Global Transcatheter Aortic Valve Replacement (TAVR) Market Growth (Status and Outlook) 2023-2029

Global Transcatheter Aortic Valve Replacement (TAVR) Market Growth (Status and Outlook) 2023-2029

Transcatheter Aortic Valve Replacement (TAVR), also referred as Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive surgical procedure repairs the valve without removing the old, damaged valve. Instead, it wedges a replacement valve into the aortic valve's place. Normally valve replacement method requires an open heart procedure with a sternotomy, in which the chest is surgically separated for the treatment. The TAVR procedures can be done through very small openings that leave all the chest bones in place.

LPI (LP Information)' newest research report, the “Transcatheter Aortic Valve Replacement (TAVR) Industry Forecast” looks at past sales and reviews total world Transcatheter Aortic Valve Replacement (TAVR) sales in 2022, providing a comprehensive analysis by region and market sector of projected Transcatheter Aortic Valve Replacement (TAVR) sales for 2023 through 2029. With Transcatheter Aortic Valve Replacement (TAVR) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transcatheter Aortic Valve Replacement (TAVR) industry.

This Insight Report provides a comprehensive analysis of the global Transcatheter Aortic Valve Replacement (TAVR) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Transcatheter Aortic Valve Replacement (TAVR) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Transcatheter Aortic Valve Replacement (TAVR) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transcatheter Aortic Valve Replacement (TAVR) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transcatheter Aortic Valve Replacement (TAVR).

The global Transcatheter Aortic Valve Replacement (TAVR) market size is projected to grow from US$ 3921.4 million in 2022 to US$ 12070 million in 2029; it is expected to grow at a CAGR of 17.4% from 2023 to 2029.

In China, Transcatheter Aortic Valve Replacement (TAVR) key players include Venus Medtech, Suzhou Jiecheng Medical Technology Co., Peijia Medical, etc.

East China is the largest consumer region of transcatheter aortic valve replacement in China, followed by North and South China.

In terms of product, Transfemoral Approach is the largest segment, with a share over 80%. And in terms of application, the largest application is Aortic Stenosis, followed by Aortic Regurgitation.

This report presents a comprehensive overview, market shares, and growth opportunities of Transcatheter Aortic Valve Replacement (TAVR) market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Transfemoral Approach
Transapical Approach
Others

Segmentation by application
Aortic Stenosis
Aortic Regurgitation
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Edwards Lifesciences
Medtronic
Abbott
Boston Scientific
Meril Life Sciences
Venus Medtech
Bracco (HLT)
JenaValve Technology
Suzhou Jiecheng Medical Technology Co.
Peijia Medical

Please note: The report will take approximately 2 business days to prepare and deliver.